Abstract Number: 2814 • 2018 ACR/ARHP Annual Meeting
Methotrexate Use and the Risk for Cardiovascular Disease Among Rheumatoid Patients Initiating Biologic Disease-Modifying Anti-Rheumatic Drugs
Background/Purpose: Methotrexate (MTX) has been associated with reduced risk for cardiovascular disease (CVD) in several studies conducted among rheumatoid arthritis (RA) patients never exposed to…Abstract Number: 504 • 2018 ACR/ARHP Annual Meeting
Views of Primary Care Physicians and Rheumatologists Regarding Screening and Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis
Background/Purpose: Screening and management of hyperlipidemia in rheumatoid arthritis (RA) is suboptimal, despite RA patients’ high risk for cardiovascular disease (CVD) mortality. Our purpose was…Abstract Number: 788 • 2018 ACR/ARHP Annual Meeting
Clinical and Echocardiographic Associates of All-Cause Mortality and Cardiovascular Outcomes in Patients with Systemic Sclerosis
Background/Purpose: Cardiac events are an important cause of mortality in Systemic Sclerosis (SSc), but its diagnosis remains challenging. Left ventricular global longitudinal strain is a…Abstract Number: 1565 • 2018 ACR/ARHP Annual Meeting
Comorbidity Burden in Primary Sjögren’s Syndrome: A Long-Term Observation in Clinical Practice
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a complex disorder that may affect any organ and system. In this new era of personalized medicine, a growing…Abstract Number: 1913 • 2018 ACR/ARHP Annual Meeting
Management of Ventricular Tachycardia and Cardiomyopathy in the Rheumatologist World: A Retrospective Review of Diagnostic Tools and Treatment Decisions for Cardiac Sarcoidosis
Background/Purpose: Cardiac sarcoidosis has been noted in 2-7% of patients with sarcoidosis. However, the incidence is >20% based on necropsy data. Given the poor yield…Abstract Number: 2817 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk with Biologics and Tofacitinib Compared to Conventional Synthetic Dmards in Patients with Rheumatoid Arthritis
Background/Purpose: Cardiovascular disease (CVD) represents the leading cause of death in RA, accounting for ~50% of excess mortality. Disease activity, strongly linked to CVD, has…Abstract Number: 505 • 2018 ACR/ARHP Annual Meeting
Impact of Biological Treatment on Left Ventricular Regional Dysfunction in Rheumatoid Arthritis Patients Determined with Global Circumferential and Longitudinal Strain Values Using Cardiac Magnetic Resonance Imaging
Background/Purpose: Congestive heart failure (CHF) is a major contributor to morbidity and mortality in patients with rheumatoid arthritis (RA). Myocardial disease is typically clinically silent,…Abstract Number: 805 • 2018 ACR/ARHP Annual Meeting
Diastolic Dysfunction in Scleroderma: An Investigation into Associated Risk Factors and Impact on Survival
Background/Purpose: Scleroderma heart disease often goes unrecognized until severe clinical manifestations are present. Diastolic dysfunction (DD) may identify patients at risk for cardiac complications by…Abstract Number: 145 • 2017 ACR/ARHP Annual Meeting
Cause-Specific Mortality in a Large Population-Based Cohort of Rheumatoid Arthritis Patients in Italy
Background/Purpose: Studies on mortality in RA from Italy are completely lacking. The aim of our study was to investigate cause-specific mortality in RA subjects living…Abstract Number: 1088 • 2017 ACR/ARHP Annual Meeting
Staff Protocol in Rheumatology Clinics Reduces Population-Level Rate of High Blood Pressure
Background/Purpose: The Centers for Disease Control and Prevention director has said “nothing will save more lives” than protocols to control blood pressure (BP). BP is…Abstract Number: 1609 • 2017 ACR/ARHP Annual Meeting
Telomere Length and Coronary Artery Atherosclerosis in Patients with Systemic Lupus Erythematosus
Background/Purpose: Coronary atherosclerosis increases with age but is more prevalent in patients with systemic lupus erythematosus (SLE) independent of chronological age; this increased prevalence has…Abstract Number: 2362 • 2017 ACR/ARHP Annual Meeting
Novel Biomarkers for the Prediction of Subclinical Coronary Artery Atherosclerosis in Patients with Rheumatoid Arthritis
Background/Purpose: Cardiovascular (CV) disease risk prediction models, that were originally developed for use in the general population, have been found to have suboptimal performance in…Abstract Number: 2937 • 2017 ACR/ARHP Annual Meeting
Genetic Variants in HLA-C and Class I Pathway Genes Influence Susceptibility to Kawasaki Disease
Background/Purpose: Host genetics influence susceptibility to Kawasaki disease (KD), an acute pediatric vasculitis, and genome wide association studies (GWAS) have detected variants with modest effects…Abstract Number: 146 • 2017 ACR/ARHP Annual Meeting
Major Cardiovascular Events Among an Inception Cohort of Seniors with Rheumatoid Arthritis
Background/Purpose: We previously observed that incident RA patients have an increased risk of cardiovascular (CV) mortality relative to the general population in Ontario. Our aim…Abstract Number: 1095 • 2017 ACR/ARHP Annual Meeting
Increasing Lipid Panel Monitoring in a Rheumatology Clinic
Background/Purpose: Patients with autoimmune conditions are at increased risk for cardiovascular disease (CVD) compared to the general population. It is not routine practice at UT…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 38
- Next Page »